Roivant Sciences Ltd. (roiv)
ROIV Financials
| Trailing P/E | N/A |
| Forward P/E | -21.44 |
| Price/Sales | 3531.06 |
| Price/Book | 6.29 |
| Market cap | $26.60B |
| Avg volume | 7245295.0 |
| Shares outstanding | 722323015.0 |
Start Free — open ROIV in Vest Terminal
Access live data, filings, ownership, and analysis for Roivant Sciences Ltd..
Roivant Sciences Ltd. FAQ
What does Roivant Sciences Ltd. (ROIV) do?
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development acros…
What is ROIV's P/E ratio?
Roivant Sciences Ltd. has a trailing P/E of N/A× based on publicly available market data.
Does ROIV pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is ROIV in?
Roivant Sciences Ltd. is classified in Healthcare (Biotechnology) on NMS.
What is ROIV's market capitalization?
Approximate market cap: $26.60B.
What are the main risks for ROIV?
Key risks include negative revenue growth, among factors on this page.
What are the strengths of ROIV?
Potential positives include moderate leverage (debt/equity 2.18), large cap scale ($26.60b) may provide distribution and funding advantages.
Where can I get analyst estimates for ROIV?
Public analyst price targets and consensus for Roivant Sciences Ltd. are on the free /stocks/roiv/estimates page. Deeper estimate history and models are available in Vest Terminal.